month of diagnosis of stage IV colorectal cancer. Patients undergoing resection had higher median survival rates when compared with patients who did not undergo resection (No resected: 5 months, vs. resected during the first month: 16 months and resected after one month: 13 months, P ¼ 0,003) . Conclusion: Most patients who present with incurable stage IV colorectal cancer undergo resection of the primary tumor. When compared with patients who did not undergo resection overall survival was better in patients undergoing resection. The results of this review support primary tumor resection in stage IV colorectal cancer. Introduction: No previous studies have evaluated clinical outcomes, such as BRAF/ KRAS mutation profiles and microsatellite instability (MSI) statuses, of ovarian metastases of colorectal cancers (CRCs). This retrospective study aimed to clarify the clinicopathological features of CRC in women with respect to somatic mutation profiles, and to evaluate the efficacy of oophorectomy for ovarian metastases of CRC. Methods: We determined the clinical prevalence of ovarian metastasis of CRC in 296 female patients identified from a cohort of 666 patients (Figure 1) , and evaluated the clinical outcomes and treatment strategies relative to mutation profiles in female patients. Additionally, we evaluated the clinicopathological features, including mutation profiles, of patients with ovarian metastases of CRC to determine the efficacy of oophorectomy. The 3-year OS rates of patients with BRAF mutation, KRAS mutation, and both wild-type genes were 43.6%, 86.5% and 73.3%, respectively (P < 0.0001). Of the 19 patients with ovarian metastases, the median survival durations after oophorectomy were 42.2 and 16.3 months for patients with curability statuses of R0/1 and R2, respectively (P ¼ 0.0034). Conclusion: Although female patients with advanced BRAF-mutant CRC had a poor prognosis, the outcomes of those with ovarian metastases were improved by oophorectomy, regardless of BRAF/KRAS mutation. pain. However, there has been limited research using SILS in colorectal cancer surgery and whether these expected benefits exist and/or outweigh the associated disadvantages e.g. longer operating time, increased equipment costs and surgical training. In addition, the oncological safety of SILS, including lymph node retrieval and port-site recurrence remains unclear. Therefore the aim of this study was to compare surgical and oncological outcomes following SILS or CL in colorectal cancer surgery. Methods: Thirty patients undergoing laparoscopic colorectal surgery for cancer were randomised for either SILS (n ¼ 16) or CL (n ¼ 14) procedure. Patients were blinded to the actual procedure until hospital discharge. Clinical outcomes included operating time, surgical procedure, blood loss, post-operative complications and length of stay as well as the tumour pathology (stage, nodal involvement, tumour site and size; where available). The study had ethics committee approval. Results: Patient demographics: the age was similar between groups SILS, 69, median (51-83, range) and CL, 70(50-83). However, there were fewer males in the SILS group (44% compared to 71% in CL) and the BMI was higher (30(16.8-45) and 26.6(19.4-31. 2) for CL). Surgical Outcomes: The ASA grade for SILS was 7 ASA II and 9 ASA III compared to CL, 3 ASA I, 7 ASA II and 5 ASA III. The surgical procedures performed in both groups included anterior resections, right and left hemi-colectomy and sigmoid colectomy. Nine patients had previous abdominal surgery (6 in SILS, 3 CL). There was no P-346 Figure 1 
